0001145197FALSE00011451972024-12-032024-12-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 3, 2024
 
INSULET CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware001-3346204-3523891
(State or Other Jurisdiction
of Incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
100 Nagog Park
ActonMassachusetts01720
(Address of Principal Executive Offices, including Zip Code)
Registrant’s telephone number, including area code:
(978)600-7000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Recommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act☐



Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share
PODDThe NASDAQ Stock Market, LLC


Item 8.01Other Events

On December 4, 2024, Insulet Corporation (the "Company") issued a press release announcing that, on December 3, 2024, after a four-week trial in the U.S. District Court for the District of Massachusetts in the manner of Insulet Corporation vs. EOFlow Co., Ltd. et al., a jury verdict was returned in favor of the Company.

The jury found that EOFlow Co., Ltd. ("EOFlow") and several other defendants misappropriated certain of the Company's trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for willful and malicious misappropriation, for a total damages award of $452 million. EOFlow's ability to satisfy this damage award is not known with certainty. EOFlow and other defendants may seek to appeal the verdict.

The Company intends to seek injunctive relief from the court in addition to the monetary damages awarded by the jury.


Item 9.01.Financial Statements and Exhibits.
(d)Exhibits.
The following exhibit is filed as part of this report:
No.Exhibit
Press Release dated December 4, 2024
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  INSULET CORPORATION
December 4, 2024  By:/s/ John W. Kapples
Name:John W. Kapples
Title:Senior Vice President, General Counsel




EXHIBIT 99.1



Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

Jury awards $452 million in damages

ACTON, Mass. - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow) in federal court.

After a four-week trial in the U.S. District Court for the District of Massachusetts in the matter of Insulet Corporation vs. EOFlow et al., a jury verdict was returned in favor of Insulet on December 3, 2024.

The jury found that EOFlow and several other defendants misappropriated Insulet’s trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for willful and malicious misappropriation, for a total damages award of $452 million. EOFlow’s ability to satisfy this damage award is not known with certainty.

"We are extremely pleased with the jury’s verdict, which validates our commitment to protecting our technology and defending our intellectual property against misappropriation and infringement," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We will not only enforce our patents, but also zealously protect our valuable trade secrets, in which we’ve invested heavily to improve the lives of people with diabetes."

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.

Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com

Media: 
Angela Geryak Wiczek 
Senior Director, Corporate Communications 
(978) 932-0611 
awiczek@insulet.com 

v3.24.3
Cover
Dec. 03, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 03, 2024
Entity Registrant Name INSULET CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-33462
Entity Central Index Key 0001145197
Amendment Flag false
Entity Tax Identification Number 04-3523891
Entity Address, Address Line One 100 Nagog Park
Entity Address, City or Town Acton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01720
City Area Code (978)
Local Phone Number 600-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value Per Share
Trading Symbol PODD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Insulet (NASDAQ:PODD)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Insulet Charts.
Insulet (NASDAQ:PODD)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Insulet Charts.